More commonly, the treatment of IBD requires aminosalicylates
Medical therapy for inflammatory bowel disease was grouped by class, including aminosalicylates
, steroids, immune modulators (azathioprine, 6-mercaptopurine, methotrexate, and cyclosporine), and anti-TNF inhibitors (infliximab and adalimumab).
Effects of aminosalicylates
on thiopurine Smethyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
He was started on aminosalicylate
therapy with marked symptom improvement.
For an individual with a heterozygous genotype to present a low-activity phenotype, the aminosalicylate
treatment would have to cause a reduction in TPMT activity up to 15-fold.
Sulfasalazine is a compound that consists of an aminosalicylate
group (5-ASA) hooked to a sulfur component.
APRISO[TM] is a locally-acting aminosalicylate
indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older.
This randomised, double-blind, placebo-controlled Phase IIIb clinical study will evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate
(5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
The study is expected to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate
(5-ASA) therapy for patients who have mild or moderate active ulcerative colitis who are not controlled on background 5-ASA therapy.
Because to the best of our knowledge there has been no systematic investigation on whether the sample pretreatment procedure influences the determination of the TPMT activity in patients receiving aminosalicylate
therapy, we performed in vitro experiments to clarify this uncertainty.
UCERIS Phase IIIb clinical study: Patient enrollment continues in a clinical study designed to evaluate whether there is an incremental benefit in remission rate when UCERIS 9 mg is added to current oral aminosalicylate
(5-ASA) therapy for patients with mild to moderate active ulcerative colitis not adequately controlled on 5-ASA therapy.
The study enrolled 299 patients whose Crohn's disease had not responded to treatment with an aminosalicylate
, steroids, or immunomodulator drugs.